- Home
- DSGX vs MIRM Comparison
DSGX vs MIRM Comparison
Compare DSGX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGX | MIRM |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.7B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DSGX | MIRM |
|---|---|---|
| Price | $69.69 | $121.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $105.22 | ★ $119.85 |
| AVG Volume (30 Days) | 601.2K | ★ 785.1K |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $12.05 | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | $37.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.56 | $47.89 |
| 52 Week High | $108.51 | $119.49 |
Technical Indicators
Market Signals| Indicator | DSGX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 78.30 |
| Support Level | $69.44 | $87.93 |
| Resistance Level | $74.57 | N/A |
| Average True Range (ATR) | 2.62 | 4.98 |
| MACD | -0.63 | 2.49 |
| Stochastic Oscillator | 37.97 | 92.80 |
Price Performance
Historical ComparisonAbout DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.